Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 9, 2004

Study Completion Date

December 20, 2006

Conditions
Macular Degeneration
Interventions
DRUG

TAC-PF

DRUG

Triamcinolone Acetonide

Trial Locations (23)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

21208

Elman Retina Group, P.A. - Pikesville (ERGPM), Pikesville

21237

Elman Retina Group, P.A. - Baltimore (ERGBM), Baltimore

22031

Retina Group of Washington - Fairfax (RGWFF), Fairfax

27710

Duke University Eye Center (DUENC), Durham

37232

Vanderbilt University, Nashville

53792

University of Wisconsin, Madison

97239

Casey Eye Institute-Portland, OR (CEIPO), Portland

Unknown

Retina Associates Southwest (RASTA), Tucson

Doheny Eye Institute, Los Angeles

Bascom Palmer Eye Institute, Miami

Central Florida Retina (CFROL), Orlando

Retina Associates of Florida, Tampa

Midwest Eye Institute, Indianapolis

VitreoRetinal Surgery (VRSMN) Center, Minneapolis

Dean McGee Eye Institute (DMEIO), Oklahoma City

Retina Northwest (RNWPO), Portland

Wills Eye Hospital, Philadelphia

Southeastern Retina Associates (SRAKT), Knoxville

Texas Retina Associates, Arlington

Texas Retina Associates, Dallas

48109-0624

University of Michigan, Ann Arbor

10021-4872

Cornell University, New York

All Listed Sponsors
lead

National Eye Institute (NEI)

NIH

NCT00100009 - Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter